Block sequential adriamycin CMF – optimal non-myeloablative chemotherapy for high risk adjuvant breast cancer?

After the publication of the 10-year survival data from Milan on the adjuvant use of the block sequential regimen consisting of four cycles of adriamycin followed by eight cycles of intravenous CMF, many centres adopted this as standard of care for high risk, multiple node-positive breast cancer. Fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Cameron, D A, Anderson, A, Toy, E, Evans, T R J, Le Vay, J H, Kennedy, I C S, Grieve, R J, Perren, T J, Jones, A, Mansi, J, Crown, J, Leonard, R C F
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2002
Materias:
Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2376297/
https://www.ncbi.nlm.nih.gov/pubmed/12454763
http://dx.doi.org/10.1038/sj.bjc.6600660

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2376297/
https://www.ncbi.nlm.nih.gov/pubmed/12454763
http://dx.doi.org/10.1038/sj.bjc.6600660

Ejemplares similares